Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879332 · ClinicalTrials.gov registry record · Phase 1
A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
A Phase 1 study, sponsored by Bial - Portela C S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01879332 is a Phase 1 study that has completed, run by Bial - Portela C S.A.. The registered enrollment target is 16 participants.
The verdict
NCT01879332, a Phase 1 study, has completed, sponsored by Bial - Portela C S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to determine a maximum tolerated dose
Interventions
- DRUG Placebo
- DRUG BIA 2-093 3000 mg once daily
- DRUG BIA 2-093 3600 mg once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01879332
The ClinicalTrials.gov registry entry for NCT01879332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bial - Portela C S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01879332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01879332 about?
NCT01879332 is a clinical study titled "A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers". Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to determine a maximum tolerated dose
What is the current status of trial NCT01879332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2006-12. Estimated completion is 2007-02.
What interventions are being tested in trial NCT01879332?
The interventions under investigation include: Placebo (DRUG), BIA 2-093 3000 mg once daily (DRUG), BIA 2-093 3600 mg once daily (DRUG).
Who is sponsoring clinical trial NCT01879332?
This trial is sponsored by Bial - Portela C S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.